Insider Insight: Marco Marcucci’s AGENUS Option Award Signals Strong Investor Confidence and Growth Potential
AGENUS insider Marcucci’s $0 stock‑option exercise signals board confidence and a cautiously optimistic outlook for its immuno‑oncology pipeline.
3 minutes to read